Invivyd
NEWS
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.
It is offering 17.7 million shares with an expected price between $16 and $18 per share. It will trade on the Nasdaq under the ADGI ticker symbol.
It was a busy week for clinical trial news. Here’s a look.
BioSpace takes a look at data released this week from some of the numerous ongoing clinical studies to advance potential therapies and treatment for disease. Here are some of them.
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
The new financing round was led by RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.
JOBS
IN THE PRESS